Coeptis在8.35亿美元的交易中收购了Z-Squed,建立了一个合并的实体,Z-Squatis股东拥有79%的股份。 Coeptis acquires Z-Squared in an $835 million deal, creating a merged entity with Z-Squared shareholders owning 79%.

Coeptis治疗公司(COEP)披露了与Z-Sqred的8.35亿美元交易,价值6.6亿美元用于Z-Squred的技术基础设施,7 500万美元用于细胞治疗和肿瘤学的生物技术分流,以及1亿美元的税款损失。 Coeptis Therapeutics (COEP) disclosed an $835 million deal with Z-Squared, valued at $660 million for Z-Squared’s tech infrastructure, $75 million for a biotech spin-out in cell therapy and oncology, and $100 million in tax-loss carry forwards. 合并后的实体将看到Z-股份股东拥有79%的股份,Coeptis 21%的股份。 The merged entity will see Z-Squared shareholders own 79%, Coeptis 21%. Z-Squred经营9 000个美国技术单位,拥有全部能力,有多样化的托管服务。 Z-Squared operates 9,000 U.S. tech units at full capacity with diversified hosting. 生物技术单位将作为一个独立公司被推出。 The biotech unit will be spun off as a standalone company. 范德堡报告分析了SEC的文件，指出其双行业结构和战略灵活性，基于公开文件且未提供投资建议。 The Vanderbilt Report analyzed SEC filings, noting the dual-sector structure and strategic flexibility, based on public documents without investment advice.